Live
MOONS'How Artemis will help the U.S. create a moon base - NBC NewsAgilentAgilent Technologies Inc (A) Shares Fall 5.0% -- What GF Score o - GuruFocusFierceBiotechDespite data concerns, Roche’s oral SERD can still be largest product in company history: execFierceBiotechRegeneron ushers in new genetic medicine era with groundbreaking gene therapy approvalThermo FisherThermo Fisher CEO says onshoring push will bring a ‘tailwind’ for the Waltham company - The Business JournalsAgilentEarnings snapshot: Agilent Technologies misses FQ1 estimates; gives FQ2 and raises FY26 outlook, above forecast - MSNThermo FisherThermo Fisher Scientific Inc. Q1 2026 Earnings Call Summary - Yahoo Finance10x Genomics BlogWhy 10x Genomics (TXG) Shares Are Trading Lower Today - TradingViewFierceBiotechKurma closes €215M Europe-focused fund to spread across 20 biotechsFierceBiotechPfizer cans work on next-gen conjugate in cancer patientsBioWorldFinancings for April 23, 2026BioWorldIn the clinic for April 23, 2026
Endpoints News 6 janv. 2026

Lilly goes back to Nimbus for an oral obesity drug in $55M deal

Lilly goes back to Nimbus for an oral obesity drug in $55M deal

Original
Contenu indisponible. Consultez la source originale.